Dr. Stephen Marx, Marx BioTechnology Ltd. “Developing Early Detection Diagnostic Kits for GVHD” Video Interview at BioInvest Israel 2012

http://marxbio.com/

Marx BioTechnology Ltd. is dedicated to providing novel diagnostic and therapeutic solutions. Using an innovative platform technology, they are developing diagnostic kits for a variety of diseases. Their current focus is on the early detection of Graft-versus-Host-Disease (GVHD). Their diagnostic kit for GVHD will provide a faster and more reliable tool than anything currently on the market. SNNLive spoke to the company’s founder and CEO, Dr. Stephen Marx, at the 2012 BioInvest Israel Conference in Haifa.

Stephen Marx received a Ph.D. in cell biology from the University of Texas. Dr. Marx has over a decade of experience in research, including a post doctoral fellowship at the Hebrew University. There he conducted research focused on cancer and transplantation. In this interview, he talks about his company’s work to combat GVHD. “Certain disorders, such as blood diseases [like Leukemia] require bone-marrow stem-cell transplants, and in 50 percent of cases, those individuals will get GVHD… it’s a very deadly disorder.” As Dr. Marx explains, what happens, essentially, is that the transplanted tissue mounts an immune response against the host’s body, attempting to destroy it.

Dr. Marx also explains how his company’s technology works. “We have diagnostic technology that has three different components. Each individual component can actually render a diagnosis of the GVHD disorder prior to the onset of observable symptoms.”
To learn more about Marx Biotechnology, visit their website. SNNLive welcomes Dr.Stephen Marx, Founder and CEO of Marx BioTechnology Ltd.